Symbols / ACET Stock $7.90 +0.00% Adicet Bio, Inc.
ACET (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Ratings
Current target
$7.90
Low
$18.00
High
$128.00
Mean
$53.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-23 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2026-03-13 | main | Guggenheim | Buy → Buy | $100 |
| 2026-01-21 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2026-01-06 | main | Canaccord Genuity | Buy → Buy | $18 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-10-08 | main | Guggenheim | Buy → Buy | $8 |
| 2025-09-19 | reit | Guggenheim | Buy → Buy | $7 |
| 2025-03-21 | reit | Guggenheim | Buy → Buy | $7 |
| 2025-03-07 | reit | Citizens Capital Markets | Market Perform → Market Perform | — |
| 2025-03-07 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-27 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-06 | reit | JMP Securities | Market Perform → Market Perform | — |
| 2025-02-05 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-19 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-18 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-14 | main | Canaccord Genuity | Buy → Buy | $19 |
| 2024-07-08 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
- Adicet Bio (NASDAQ:ACET) Stock Passes Below Two Hundred Day Moving Average - Here's Why - MarketBeat ue, 21 Apr 2026 07
- OrbiMed Advisors sells Adicet Bio (ACET) stock worth $674,847 - Investing.com hu, 09 Apr 2026 07
- Adicet Bio (ACET) Upgraded to Buy: Here's Why - Yahoo Finance ue, 24 Mar 2026 07
- $ACET stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Mon, 05 Jan 2026 08
- Adicet Bio (ACET) CEO granted 468,555 stock options at $6.81 strike - Stock Titan Fri, 27 Mar 2026 07
- Adicet Bio (ACET) Innovation Pipeline | Adicet Bio Inc. posts wider loss vs estimates, no revenue - Trading Community - Cổng thông tin điện tử tỉnh Tây Ninh hu, 23 Apr 2026 02
- Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat ue, 21 Apr 2026 12
- Latest ACET News - Adicet Bio Reports Fourth Quarter and Full ... - Stock Titan Fri, 28 Nov 2025 08
- Ra Capital buys Adicet Bio (ACET) shares worth $1.6 million - Investing.com Mon, 13 Apr 2026 07
- Insider Sale: 10% owner at $ACET Sells 29,319 Shares - Quiver Quantitative hu, 09 Apr 2026 07
- Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell? - MarketBeat ue, 07 Apr 2026 07
- RA Capital and partners disclose stake in Adicet Bio (NASDAQ: ACET) - Stock Titan Mon, 13 Apr 2026 21
- Ra Capital Management, L.P. Buys 74,751 Shares of Adicet Bio (NASDAQ:ACET) Stock - MarketBeat Mon, 13 Apr 2026 07
- RA Capital boosts Adicet Bio (ACET) stake with open-market share purchases - Stock Titan Mon, 13 Apr 2026 07
- Biotech maps 2026 test plans for cell therapies in lupus and cancer - Stock Titan Wed, 07 Jan 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
24.99
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
24.99
|
| Operating Expense |
|
122.11
-4.31%
|
127.61
-3.74%
|
132.58
+35.92%
|
97.54
|
| Research And Development |
|
99.13
-0.20%
|
99.32
-6.34%
|
106.04
+48.84%
|
71.25
|
| Selling General And Administration |
|
22.99
-18.75%
|
28.29
+6.63%
|
26.53
+0.91%
|
26.30
|
| General And Administrative Expense |
|
22.99
-18.75%
|
28.29
+6.63%
|
26.53
+0.91%
|
26.30
|
| Other Gand A |
|
22.99
-18.75%
|
28.29
+6.63%
|
26.53
+0.91%
|
26.30
|
| Total Expenses |
|
122.11
-4.31%
|
127.61
-3.74%
|
132.58
+35.92%
|
97.54
|
| Operating Income |
|
-122.11
+4.31%
|
-127.61
+3.74%
|
-132.58
-82.73%
|
-72.55
|
| Total Operating Income As Reported |
|
-122.11
+4.31%
|
-127.61
+16.06%
|
-152.04
-109.56%
|
-72.55
|
| EBITDA |
|
-110.39
+0.24%
|
-110.65
+18.96%
|
-136.53
-103.37%
|
-67.14
|
| Normalized EBITDA |
|
-110.39
+0.24%
|
-110.65
+5.49%
|
-117.07
-74.38%
|
-67.14
|
| Reconciled Depreciation |
|
6.38
-1.35%
|
6.47
+6.07%
|
6.10
+136.82%
|
2.58
|
| EBIT |
|
-116.77
+0.30%
|
-117.12
+17.89%
|
-142.63
-104.61%
|
-69.71
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-19.46
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-19.46
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-19.46
|
0.00
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
19.46
|
0.00
|
| Net Income |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Pretax Income |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Net Non Operating Interest Income Expense |
|
5.74
-46.40%
|
10.71
+7.61%
|
9.95
+170.46%
|
3.68
|
| Interest Expense Non Operating |
|
0.04
+800.00%
|
0.00
-84.00%
|
0.03
-68.75%
|
0.08
|
| Net Interest Income |
|
5.74
-46.40%
|
10.71
+7.61%
|
9.95
+170.46%
|
3.68
|
| Interest Expense |
|
0.04
+800.00%
|
0.00
-84.00%
|
0.03
-68.75%
|
0.08
|
| Interest Income Non Operating |
|
5.78
-46.08%
|
10.71
+7.38%
|
9.98
+165.37%
|
3.76
|
| Interest Income |
|
5.78
-46.08%
|
10.71
+7.38%
|
9.98
+165.37%
|
3.76
|
| Other Income Expense |
|
-0.43
-98.16%
|
-0.22
+98.92%
|
-20.04
-2080.09%
|
-0.92
|
| Other Non Operating Income Expenses |
|
-0.43
-98.16%
|
-0.22
+62.13%
|
-0.57
+37.65%
|
-0.92
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Net Income From Continuing Operation Net Minority Interest |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Net Income From Continuing And Discontinued Operation |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Net Income Continuous Operations |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Normalized Income |
|
-116.80
+0.27%
|
-117.12
+4.93%
|
-123.20
-76.52%
|
-69.79
|
| Net Income Common Stockholders |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Diluted EPS |
|
-16.95
+20.35%
|
-21.28
+59.82%
|
-52.96
-94.71%
|
-27.20
|
| Basic EPS |
|
-16.95
+20.35%
|
-21.28
+59.82%
|
-52.96
-94.71%
|
-27.20
|
| Basic Average Shares |
|
6.89
+25.49%
|
5.49
+104.14%
|
2.69
+4.78%
|
2.57
|
| Diluted Average Shares |
|
6.89
+25.49%
|
5.49
+104.14%
|
2.69
+4.78%
|
2.57
|
| Diluted NI Availto Com Stockholders |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
192.35
-12.65%
|
220.22
+6.23%
|
207.29
-37.31%
|
330.69
|
| Current Assets |
|
160.93
-10.66%
|
180.14
+11.01%
|
162.27
-37.84%
|
261.04
|
| Cash Cash Equivalents And Short Term Investments |
|
158.53
-10.08%
|
176.30
+10.39%
|
159.71
-38.01%
|
257.66
|
| Cash And Cash Equivalents |
|
38.92
-31.11%
|
56.49
-64.63%
|
159.71
-38.01%
|
257.66
|
| Other Short Term Investments |
|
119.61
-0.16%
|
119.81
|
0.00
|
—
|
| Receivables |
|
0.34
+252.58%
|
0.10
|
0.00
-100.00%
|
0.43
|
| Accounts Receivable |
|
—
|
—
|
—
|
0.00
|
| Taxes Receivable |
|
—
|
—
|
—
|
—
|
| Accrued Interest Receivable |
|
0.34
+252.58%
|
0.10
|
0.00
-100.00%
|
0.43
|
| Prepaid Assets |
|
1.73
-42.18%
|
3.00
+42.54%
|
2.10
-19.42%
|
2.61
|
| Other Current Assets |
|
0.32
-56.58%
|
0.74
+61.27%
|
0.46
+36.01%
|
0.34
|
| Total Non Current Assets |
|
31.43
-21.59%
|
40.08
-10.97%
|
45.02
-35.36%
|
69.65
|
| Net PPE |
|
28.48
-22.50%
|
36.75
-16.85%
|
44.20
-9.76%
|
48.98
|
| Gross PPE |
|
55.87
-3.79%
|
58.07
-1.66%
|
59.05
+2.28%
|
57.73
|
| Accumulated Depreciation |
|
-27.39
-28.49%
|
-21.32
-43.56%
|
-14.85
-69.62%
|
-8.75
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
1.57
+1.29%
|
1.55
+0.19%
|
1.55
+118.76%
|
0.71
|
| Construction In Progress |
|
0.20
+0.00%
|
0.20
-25.28%
|
0.27
-97.15%
|
9.29
|
| Other Properties |
|
25.67
-8.59%
|
28.09
-8.18%
|
30.59
+10.14%
|
27.77
|
| Leases |
|
28.42
+0.69%
|
28.23
+5.95%
|
26.64
+33.49%
|
19.96
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
0.00
-100.00%
|
19.46
|
| Goodwill |
|
—
|
—
|
0.00
-100.00%
|
19.46
|
| Investments And Advances |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
2.95
-11.50%
|
3.33
+305.23%
|
0.82
-32.12%
|
1.21
|
| Total Liabilities Net Minority Interest |
|
33.15
-1.38%
|
33.61
-9.46%
|
37.12
-3.21%
|
38.35
|
| Current Liabilities |
|
21.53
+11.03%
|
19.39
+0.54%
|
19.29
-2.13%
|
19.71
|
| Payables And Accrued Expenses |
|
12.71
+38.97%
|
9.15
-4.23%
|
9.55
-17.03%
|
11.51
|
| Payables |
|
4.74
-1.88%
|
4.83
+84.00%
|
2.62
-40.40%
|
4.40
|
| Accounts Payable |
|
4.74
-1.88%
|
4.83
+84.00%
|
2.62
-40.40%
|
4.40
|
| Current Accrued Expenses |
|
7.97
+84.67%
|
4.32
-37.66%
|
6.93
-2.55%
|
7.11
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.63
-20.81%
|
7.11
+9.18%
|
6.51
+14.22%
|
5.70
|
| Current Debt And Capital Lease Obligation |
|
3.19
+1.72%
|
3.13
-2.76%
|
3.22
+29.25%
|
2.49
|
| Current Capital Lease Obligation |
|
3.19
+1.72%
|
3.13
-2.76%
|
3.22
+29.25%
|
2.49
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
11.61
-18.31%
|
14.22
-20.27%
|
17.83
-4.36%
|
18.64
|
| Long Term Debt And Capital Lease Obligation |
|
11.55
-18.08%
|
14.10
-20.34%
|
17.70
-4.47%
|
18.53
|
| Long Term Capital Lease Obligation |
|
11.55
-18.08%
|
14.10
-20.34%
|
17.70
-4.47%
|
18.53
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
0.06
-46.55%
|
0.12
-10.77%
|
0.13
+14.04%
|
0.11
|
| Stockholders Equity |
|
159.21
-14.68%
|
186.61
+9.66%
|
170.18
-41.79%
|
292.34
|
| Common Stock Equity |
|
159.21
-14.68%
|
186.61
+9.66%
|
170.18
-41.79%
|
292.34
|
| Capital Stock |
|
0.01
+100.00%
|
0.01
+25.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.01
+100.00%
|
0.01
+25.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
9.59
+85.77%
|
5.16
+90.82%
|
2.70
+0.73%
|
2.68
|
| Ordinary Shares Number |
|
9.59
+85.77%
|
5.16
+90.82%
|
2.70
+0.73%
|
2.68
|
| Additional Paid In Capital |
|
773.79
+13.05%
|
684.48
+24.24%
|
550.94
+3.86%
|
530.45
|
| Retained Earnings |
|
-614.70
-23.46%
|
-497.89
-30.76%
|
-380.77
-59.91%
|
-238.11
|
| Gains Losses Not Affecting Retained Earnings |
|
0.10
+537.50%
|
0.02
|
0.00
|
0.00
|
| Other Equity Adjustments |
|
0.10
+537.50%
|
0.02
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
159.21
-14.68%
|
186.61
+9.66%
|
170.18
-41.79%
|
292.34
|
| Total Capitalization |
|
159.21
-14.68%
|
186.61
+9.66%
|
170.18
-41.79%
|
292.34
|
| Working Capital |
|
139.40
-13.28%
|
160.74
+12.42%
|
142.99
-40.75%
|
241.33
|
| Invested Capital |
|
159.21
-14.68%
|
186.61
+9.66%
|
170.18
-41.79%
|
292.34
|
| Total Debt |
|
14.74
-14.48%
|
17.23
-17.64%
|
20.92
-0.47%
|
21.02
|
| Capital Lease Obligations |
|
14.74
-14.48%
|
17.23
-17.64%
|
20.92
-0.47%
|
21.02
|
| Net Tangible Assets |
|
159.21
-14.68%
|
186.61
+9.66%
|
170.18
-37.64%
|
272.88
|
| Tangible Book Value |
|
159.21
-14.68%
|
186.61
+9.66%
|
170.18
-37.64%
|
272.88
|
| Held To Maturity Securities |
|
—
|
—
|
—
|
—
|
| Investmentin Financial Assets |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-95.25
-3.10%
|
-92.38
+1.43%
|
-93.72
-109.35%
|
-44.77
|
| Cash Flow From Continuing Operating Activities |
|
-95.25
-3.10%
|
-92.38
+1.43%
|
-93.72
-109.35%
|
-44.77
|
| Net Income From Continuing Operations |
|
-116.80
+0.27%
|
-117.12
+17.90%
|
-142.66
-104.41%
|
-69.79
|
| Depreciation Amortization Depletion |
|
6.38
-1.35%
|
6.47
+6.07%
|
6.10
+136.82%
|
2.58
|
| Depreciation And Amortization |
|
6.38
-1.35%
|
6.47
+6.07%
|
6.10
+136.82%
|
2.58
|
| Other Non Cash Items |
|
3.43
+5.87%
|
3.24
+12.60%
|
2.87
+13.78%
|
2.53
|
| Stock Based Compensation |
|
14.27
-35.83%
|
22.23
+9.74%
|
20.26
+18.29%
|
17.13
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
19.46
|
0.00
|
| Operating Gains Losses |
|
0.10
|
—
|
-0.00
-107.41%
|
0.05
|
| Gain Loss On Sale Of PPE |
|
0.10
|
0.00
+100.00%
|
-0.00
-107.41%
|
0.05
|
| Change In Working Capital |
|
1.47
+126.66%
|
-5.53
-2292.46%
|
0.25
-90.82%
|
2.74
|
| Change In Receivables |
|
—
|
—
|
—
|
0.18
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
0.18
|
| Change In Prepaid Assets |
|
1.68
+232.26%
|
-1.27
-237.26%
|
0.93
-31.05%
|
1.34
|
| Change In Payables And Accrued Expense |
|
2.93
+420.20%
|
-0.92
+1.82%
|
-0.93
-112.37%
|
7.54
|
| Change In Accrued Expense |
|
1.90
+194.16%
|
-2.02
-369.60%
|
0.75
-87.14%
|
5.83
|
| Change In Payable |
|
1.03
-6.96%
|
1.11
+165.72%
|
-1.68
-198.42%
|
1.71
|
| Change In Account Payable |
|
1.03
-6.96%
|
1.11
+165.72%
|
-1.68
-198.42%
|
1.71
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-4.80
|
| Change In Other Current Assets |
|
0.31
-12.75%
|
0.35
-1.40%
|
0.36
-61.46%
|
0.93
|
| Change In Other Current Liabilities |
|
-3.45
+6.56%
|
-3.69
-3628.28%
|
-0.10
+95.63%
|
-2.26
|
| Investing Cash Flow |
|
2.39
+102.01%
|
-119.24
-2571.19%
|
-4.46
+73.40%
|
-16.78
|
| Cash Flow From Continuing Investing Activities |
|
2.39
+102.01%
|
-119.24
-2571.19%
|
-4.46
+73.40%
|
-16.78
|
| Net PPE Purchase And Sale |
|
-1.74
-55.46%
|
-1.12
+74.96%
|
-4.46
+73.40%
|
-16.78
|
| Purchase Of PPE |
|
-1.74
-55.46%
|
-1.12
+74.96%
|
-4.46
+73.40%
|
-16.78
|
| Capital Expenditure |
|
-1.74
-55.46%
|
-1.12
+74.96%
|
-4.46
+73.40%
|
-16.78
|
| Net Investment Purchase And Sale |
|
4.13
+103.50%
|
-118.12
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-140.87
-9.10%
|
-129.12
|
0.00
|
—
|
| Sale Of Investment |
|
145.00
+1218.18%
|
11.00
|
0.00
|
0.00
|
| Financing Cash Flow |
|
75.25
-32.40%
|
111.31
+47063.98%
|
0.24
-99.43%
|
41.51
|
| Cash Flow From Continuing Financing Activities |
|
75.25
-32.40%
|
111.31
+47063.98%
|
0.24
-99.43%
|
41.51
|
| Net Issuance Payments Of Debt |
|
-0.15
|
0.00
|
—
|
—
|
| Repayment Of Debt |
|
-0.15
|
0.00
|
—
|
—
|
| Long Term Debt Payments |
|
-0.15
|
0.00
|
—
|
—
|
| Net Long Term Debt Issuance |
|
-0.15
|
0.00
|
—
|
—
|
| Net Common Stock Issuance |
|
75.17
-32.23%
|
110.92
|
0.00
-100.00%
|
43.36
|
| Proceeds From Stock Option Exercised |
|
0.33
-38.30%
|
0.53
+37.31%
|
0.39
-77.90%
|
1.75
|
| Net Other Financing Charges |
|
-0.10
+26.24%
|
-0.14
+6.00%
|
-0.15
+95.83%
|
-3.60
|
| Changes In Cash |
|
-17.61
+82.45%
|
-100.31
-2.42%
|
-97.94
-388.80%
|
-20.04
|
| Beginning Cash Position |
|
59.40
-62.81%
|
159.71
-38.01%
|
257.66
-7.22%
|
277.69
|
| End Cash Position |
|
41.79
-29.64%
|
59.40
-62.81%
|
159.71
-38.01%
|
257.66
|
| Free Cash Flow |
|
-96.98
-3.73%
|
-93.50
+4.77%
|
-98.18
-59.52%
|
-61.55
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Amortization Of Securities |
|
-4.09
-145.38%
|
-1.67
|
0.00
|
0.00
|
| Common Stock Issuance |
|
75.17
-32.23%
|
110.92
|
0.00
-100.00%
|
43.36
|
| Issuance Of Capital Stock |
|
75.17
-32.23%
|
110.92
|
0.00
-100.00%
|
43.36
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-13 View
- 42026-04-09 View
- 42026-03-27 View
- 42026-03-27 View
- 42026-03-27 View
- 42026-03-27 View
- 42026-03-27 View
- 10-K2026-03-12 View
- 8-K2026-03-12 View
- 42026-01-27 View
- 42026-01-27 View
- 42026-01-27 View
- 42026-01-27 View
- 8-K2026-01-07 View
- 8-K2025-12-29 View
- 8-K2025-12-19 View
- 10-Q2025-11-05 View
- 8-K2025-11-05 View
- 42025-10-10 View
- 8-K2025-10-07 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|